- Rapid testing for SARS-CoV-2 antigen within 15 minutes
- Facilitates patient treatment decisions quickly
- Simple, time-saving procedure
- All necessary reagents provided & no equipment needed. High sensitivity and specificity
- Intended Use: The SARS-CoV-2 Antigen Rapid Test is intended for in vitro qualitative detection to SARS-CoV-2 antigen in human nasopharyngeal swab or oropharyngeal swab samples.
The Panodyne SARS-COV-2 Antigen Rapid Test Kit uses a specially designed swab to determine whether or not a person is currently infected with COVID-19. The swab is inserted into the nostril and mouth to take samples from the nasal cavity and tonsils.
Collected samples are then placed into an extraction tube that contains approximately 0.5ml of a specially designed virus preservation solution. After just 2 minutes, the specimen is placed on a testing cassette, and an accurate result is revealed within 15 minutes.
The accuracy ratings for the Panodyne Antigen Test Kit are up to 98% accurate and it can be used by medical professionals to confirm current infection. Data collected from test results can be used to investigate the spread of the virus, further inform safe working practices and help to curb the virus.
The current Covid-19 testing process can be highly invasive and time-consuming. Our swab measures just 15cm, making it more comfortable for patients, in particular younger children who may not fully understand current circumstances.
The novel coronaviruses belong to the β genus. SARS-CoV-2 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhoea are found in a few cases. The antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.
Panodyne Lateral Flow Performance Characteristics
SARS-CoV-2 Antigen Rapid Test Performance with Comparator Method (nasopharyngeal swab/oropharyngeal swab)
PPA: 90.91% (95%CI: 76.43%-96.86%)
NPA: 99.02% (95%CI: 94.66%-99.83%)
OPA: 97.04% (95%CI: 92.63%-98.84%)
EXPLANATION OF TERMS:
PPA: Positive Percent Agreement = True Positives / True Positives + False Negatives
NPA: Negative Percent Agreement = True Negatives / True Negatives + False Positives.
OPA: Overall Percent Agreement = True Positives + True Negatives / Total
COVID-19 Testing Kits